Literature DB >> 1557997

Chylomicronemia syndrome.

A Chait1, J D Brunzell.   

Abstract

This chapter has outlined the reasons for the development of marked elevations of triglycerides that can be associated with the chylomicronemia syndrome. The clinical features of the syndrome have been discussed, with particular emphasis on chylomicron-induced pancreatitis, since this can be life-threatening. An approach to the diagnosis and management of this syndrome has been provided, with emphasis on the need for long-term follow-up and compliance to keep plasma triglycerides to a reasonable level and thereby avoid recurrent clinical complications due to chronic chylomicronemia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1557997

Source DB:  PubMed          Journal:  Adv Intern Med        ISSN: 0065-2822


  27 in total

1.  GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia.

Authors:  Xuchen Hu; Geesje M Dallinga-Thie; G Kees Hovingh; Sandy Y Chang; Norma P Sandoval; Tiffany Ly P Dang; Isamu Fukamachi; Kazuya Miyashita; Katsuyuki Nakajima; Masami Murakami; Loren G Fong; Michael Ploug; Stephen G Young; Anne P Beigneux
Journal:  J Clin Lipidol       Date:  2017-06-13       Impact factor: 4.766

Review 2.  Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.

Authors:  Werner J Geldenhuys; Li Lin; Altaf S Darvesh; Prabodh Sadana
Journal:  Drug Discov Today       Date:  2016-10-19       Impact factor: 7.851

Review 3.  Treatment of hypertriglyceridemia.

Authors:  Warren H Capell; Robert H Eckel
Journal:  Curr Diab Rep       Date:  2006-06       Impact factor: 4.810

Review 4.  Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies.

Authors:  Prashanth Rawla; Tagore Sunkara; Krishna Chaitanya Thandra; Vinaya Gaduputi
Journal:  Clin J Gastroenterol       Date:  2018-06-19

5.  Therapeutic ultrasound: Increased HDL-Cholesterol following infusions of acoustic microspheres and apolipoprotein A-I plasmids.

Authors:  Jason W Castle; Kevin P Kent; Ying Fan; Kirk D Wallace; Cynthia E L Davis; Jeannette C Roberts; Michael E Marino; Kai E Thomenius; Hae W Lim; Eric Coles; Michael H Davidson; Steven B Feinstein; Anthony DeMaria
Journal:  Atherosclerosis       Date:  2015-05-05       Impact factor: 5.162

Review 6.  Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk.

Authors:  Jila Kaberi Otarod; Ira J Goldberg
Journal:  Curr Atheroscler Rep       Date:  2004-09       Impact factor: 5.113

Review 7.  Management of hypertriglyceridemia in the diabetic patient.

Authors:  Ishwarlal Jialal; William Amess; Manpreet Kaur
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

Review 8.  Lipoprotein size and susceptibility to atherosclerosis--insights from genetically modified mouse models.

Authors:  Murielle M Véniant; Anne P Beigneux; André Bensadoun; Loren G Fong; Stephen G Young
Journal:  Curr Drug Targets       Date:  2008-03       Impact factor: 3.465

Review 9.  Triglyceride Treatment in the Age of Cholesterol Reduction.

Authors:  Nidhi Agrawal; Patricia Freitas Corradi; Namrata Gumaste; Ira J Goldberg
Journal:  Prog Cardiovasc Dis       Date:  2016-08-17       Impact factor: 8.194

10.  Lipoprotein lipase activity and mass, apolipoprotein C-II mass and polymorphisms of apolipoproteins E and A5 in subjects with prior acute hypertriglyceridaemic pancreatitis.

Authors:  Inmaculada Coca-Prieto; Pedro Valdivielso; Gunilla Olivecrona; María José Ariza; José Rioja; Pilar Font-Ugalde; Carlota García-Arias; Pedro González-Santos
Journal:  BMC Gastroenterol       Date:  2009-06-17       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.